🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSide Effects & ManagementDizziness and orthostatic hypotension on GLP-1 — when BP drops too fast

Dizziness and orthostatic hypotension on GLP-1 — when BP drops too fast

Dr.RaviCardio Thu, May 21, 2026 at 11:46 PM 5 replies 363 viewsPage 1 of 1
Dr.RaviCardio
VIP Member
2,890
15,678
Jan 2024
New York, NY
May 21, 2026 at 11:46 PM#1

Putting this up now rather than when I am certain, because by then it will not help anybody.

The nausea I get is not really nausea, it is an aversion. Food I want in the abstract becomes repellent in front of me, which no side-effect list describes.

The meal advice is right and incomplete without the hydration point. People stop drinking because drinking makes them feel full, then attribute dehydration symptoms to the drug.

What to check: Trial-level incidence runs roughly 20 to 25% for nausea at the higher dose tiers and 12 to 17% for diarrhoea, with most events mild to moderate and concentrated in the weeks after each escalation.

If your experience contradicts this, say so in the thread — I would rather be corrected here than have people act on a warning that does not hold.

50 20pete_manc_UK, anna.melb_AU, mark_tokyo and 47 others
Reply Quote Save Share Report
LabKate
Senior Member
2,678
11,234
Jan 2024
Oregon
May 21, 2026 at 11:52 PM#2
Dr.RaviCardio said:
The nausea I get is not really nausea, it is an aversion.

Agreeing with Dr.RaviCardio, and the qualification matters more than the agreement. The practical protocol is dull and it works: smaller meals, stop eating at the first sign of fullness rather than at the end of the plate, drop the fat fraction of meals in the two days after dosing, and do not lie down straight after eating. Most of what people call unmanageable nausea is a meal-size and meal-composition problem interacting with a stomach that is emptying slowly.

Correct me if the detail matters more than I have assumed.

49 19laura_annarbor, JenMemphis, pat_auckland and 46 others
Reply Quote Save Share Report
FDA_TrackerJim
Senior Member
1,567
7,890
Feb 2024
Rockville, MD
May 21, 2026 at 11:58 PM#3
Dr.RaviCardio said:
The nausea I get is not really nausea, it is an aversion.

I dislike how confidently this board tells people to push through. Incidence figures around 20 to 25% at the higher doses are class-typical, but the trials also had a discontinuation column, and "manageable with protocols" is not the same as manageable for everyone.

Last edited: May 22, 2026 at 2:58 AM
48 18MikeNYC_runner and 45 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
Dr.CardioMD
VIP Member
2,678
14,567
Dec 2023
Cleveland, OH
May 22, 2026 at 12:04 AM#4

Short answer first, then the reasoning. Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts. Receptor-level tachyphylaxis to the delayed-emptying effect develops over weeks while the central appetite effect persists, so the same dose is materially more comfortable at week six than at week two. A slower ladder therefore reaches the same dose with less cumulative nausea, not the same nausea spread thinner.

Last edited: May 22, 2026 at 6:04 AM
47 17roxy_nash, tony_orlando, Dr.NephBHM_UK and 44 others
Reply Quote Save Share Report
pam_stl
Member
267
1,123
Oct 2024
St. Louis, MO
May 22, 2026 at 12:32 AM#5
LabKate said:
The practical protocol is dull and it works: smaller meals, stop eating at the first sign of fullness rather than at the end of the plate, drop the…

This matches mine closely enough to be worth saying so out loud. Nothing to add that would improve it.

Last edited: May 22, 2026 at 5:32 AM
46 16RegAffairsDC, BiostatsBrad, PeptideSynthNJ and 43 others
Reply Quote Save Share Report

Similar Threads

Nausea incidence by dose tier — STEP and SURMOUNT meta-analysis16 replies
Constipation on GLP-1: pathophysiology and fiber protocol5 replies
Alopecia on GLP-1 — telogen effluvium differential diagnosis3 replies
Gallbladder disease risk — cholelithiasis data from clinical trials12 replies
Pancreatitis risk assessment — pooled safety analysis15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register